IPR ABC | Preliminary novelty search and FTO analysis as a part of IPR strategy

Intellectual property rights are an important part of a company’s operational planning and activities, generating added value for the business. Creating this value requires that protection is directed at the right matters and at the right time in order to gain a competitive advantage and enable risk management. A preliminary novelty search and a FTO analysis are therefore important tools for managing a company’s intangible assets.

Is my invention patentable?

A patentable invention must be new and inventive in relation to the prior art, meaning publicly available information. This public information includes all types of public disclosures in addition to patent applications and granted patents, such as journal articles, trade fair brochures, and video recordings. As the name suggests, a preliminary novelty search is used to assess whether an invention is new. The search uses databases that include not only patent publications and applications but also scientific articles. In particular, analyzing granted patents and patent applications requires interpretation and understanding of text that is specific to the patent field. With the help of a professional, even non-obvious similarities can be identified in the search. In the analysis, the features of the invention are compared with the prior art, and to meet the novelty requirement it is sufficient that the invention contains at least one new technical feature. On the other hand, novelty may be prevented by features that appear implicitly in a reference publication—features that are not explicitly mentioned but can be inferred as part of the solution described in that reference.

What is determined in a preliminary novelty search?

A preliminary novelty search includes the analysis of public information that relates closely to the invention, highlighting differences and similarities and thereby indicating how these should be taken into account in product development in order to avoid problems related to intellectual property rights. Companies often know how their inventions differ from the products of their main competitors, but a novelty search helps identify possible obstacles to patenting. Therefore, the search should be directed at the right targets by identifying the core invention and its key features. If necessary, the novelty search can be expanded into a patentability search, in which inventiveness is assessed in addition to novelty. Inventiveness requires a significant difference compared to the prior art, using analytical models commonly applied in the field to determine inventive step. However, the assessment of inventiveness varies from country to country, making it more challenging to evaluate than novelty.

Does my product infringe someone else’s patent?

A FTO analysis is a search used to determine whether a product can be commercialized freely without infringing a granted patent or a pending patent application. While a preliminary novelty search compares the client’s invention to all publicly available information, an FTO analysis focuses on the actual product or method and potential product infringements. In an FTO analysis, the scope of protection defined by the patent claims of granted patents and pending patent applications is examined.

When should a FTO analysis be conducted?

It is advisable to assess freedom to operate before launching a product—preferably during product development. In particular, the analysis should ideally be conducted before the prototype stage so that the company can ensure that competitors do not have patents or pending applications that could hinder its activities. Conducting a FTO analysis can help avoid infringing others’ patents while also building confidence in bringing one’s own product to market. The analysis thus provides an advantage by helping identify the product’s market position in light of competitors’ patents. Commissioning an FTO analysis may also help avoid patent infringement litigation in court, which can require significant company resources such as time and money.

Did this topic raise questions? Don’t hesitate to contact our experts!

UKIPO fees to increase from 1st April 2026

The UK Intellectual Property Office (UKIPO) has announced that official fees for patents, trade marks and registered industrial designs will increase as of 1 April 2026. This marks the first significant fee adjustment at the UKIPO in many years. The fees have not increased since 2018 for patents, 2016 for designs and 1998 for trade marks.

Average level of fee increases

Fees will increase by an average of 25%. The increase is most significant for patent related fees, at about 33% on average. The fees for trade marks and registered designs will be increasing by about 23% on average. The fee increase concerns both filing fees and renewal fees.

Impact on clients

This will affect many of our client’s who, partly due to Brexit, owns national rights in the United Kingdom. In cases where renewal fees are due soon after the fee increase, we recommend paying the fees before 1 April 2026 so as to save on maintenance costs.

The new fee tables can be accessed here.


If you have any questions regarding this, please contact one of our patent or trade mark attorneys. 

We have been awarded an Age Certificate

Age Certificate as recognition of our responsibility work

Laine IP Oy has been awarded the Age Certificate in recognition of our work to promote age diversity and equality. The certificate is granted by Excellence Finland, and for us it is a valued acknowledgment that our responsibility efforts are reflected in our everyday practices.

A multi-generational workplace as a strength

In our line of work, experience, new ways of thinking and continuous learning go hand in hand. It is important to us that our workplace includes professionals of different ages and at various stages of their careers. A diverse age structure brings broader perspective to our work and strengthens our ability to serve our clients with high quality.

In our daily work, this is especially visible through knowledge sharing: our more experienced experts guide and mentor younger colleagues. In this way, tacit knowledge, practical experience and best practices are passed forward, and younger professionals gradually grow into experienced experts in the field. At the same time, we ensure that our expertise remains strong in the future.

Equal opportunities to grow and develop

Applying for the Age Certificate was a natural part of our responsibility work. We want to ensure that every employee has equal opportunities to develop, learn and build a long-term career, regardless of age or life stage.

The certificate is an important recognition for us — but above all, it is a thank you to our people. A skilled, supportive, and multi-generational workplace is the foundation of our operations today and in the future.


Any questions? Please contact our sustainability lead Kathy Wasström


WTR1000 2026 | Survey results are out!

”A trusted advisor dedicated to building lasting client relationships”

”Always a step ahead”

”Commercially astute”

”Alive to business concerns”

”Boasting profound legal knowledge”


These are just some of the comments given by our clients and peers accross the world about our services. We have nothing to add but our heartfelt thanks to everyone who contributed!

Laine IP Oy maintained the Silver ranking in the WTR1000 2026 survey. Our recommended individuals are:

Congratulations to all recognized!

We are grateful of your trust and our promise is to push even further to help our clients to succeed! 

Patentable technical fields of chemistry and biotechnology, and the restrictions to consider

When talking about patenting, attention these days is often focused on utilizing AI and on new digital technologies.

At the same time, patenting is constantly solving issues that combine science, business and a very specific regulatory environment, where it might not be enough to rely on interpretations by AI.

In the fields of chemistry and biotechnology, many limitations on patenting relate to technical character and ethics – exclusive rights are not granted to discoveries found in nature, or to methods for maintaining life.

Medical inventions – where to draw the line between patentable and non-patentable inventions?

In Europe, the methods of treatment themselves cannot be patented. Surgical, therapeutic and certain diagnostic methods applied directly to human patients or animals are excluded from patent protection. Patents are therefore not granted for methods used, for example, by a physician when treating a patient. The aim is to ensure that the work of healthcare professionals is not restricted by patents.

Instead, patent protection may be obtained, e.g., for:

•    pharmaceuticals and medicinal products

•    new uses for known substances such as pharmaceuticals

•    medical devices and many diagnostic solutions

Whether an invention is described as a product or a method of treatment is often crucial.

There is typically more freedom on the cosmetic side, but the distinction between cosmetic and therapeutic use of a product can be surprisingly challenging.

Also in diagnostics, there are similar challenges related to borderlines. Methods that directly target the patient, including all diagnostic steps, may fall outside the scope of protection, while laboratory analyses, equipment, and test systems are typically patentable.

Methods in the field of biotechnology – when is there enough technicality?

In biotechnology, one key issue is the technical character of the invention. Purely biological crossbreeding and selection, generally, does not enjoy patent protection in Europe. Similarly, discoveries, such as naturally occurring agents, cannot be protected as such. However, biological material that has been isolated from nature may be patentable, since biotechnology-related patents generally cover technically controlled solutions that utilize microbiological or genetic engineering techniques. A component isolated from the human body or produced by means of a technical process, such as a gene sequence or partial gene sequence, may be patentable. In addition, inventions concerning plants or animals are patentable if their application is not technically confined to a single plant or animal variety. In inventions related to the field of biotechnology, there is also a specific requirement that the biological material be deposited in an approved depositary institution. This measure ensures the reproducibility of the invention. It is possible to request a sample from the deposited material.

When it comes to biotechnology, ethical considerations often have to be taken into account. It is good to be aware that not all biological material of human origin or its use, for example, can be protected, at least not without precise boundary conditions.

The patent strategy is sector-specific

In chemical and biotechnology inventions, very formal details can determine whether protection is available at all. Therefore, in these areas, patent strategy goes hand in hand with technical understanding and knowledge of industry-specific regulation.

Well-designed protection supports product development, investor discussions and international growth and ensures that valuable innovation protects exactly what it should.


Any questions? Please contact Kathy kathy.wasstrom@laineip.fi or Jasmin jasmin.kaivola@laineip.fi

New Sprint funding has opened

Sprint funding call opens in early 2026

Business Finland opened the Sprint funding call in early 2026 for small companies with a new innovation and strong potential for rapid international growth. Launched as a pilot, Sprint funding is primarily intended as a first R&D funding instrument for new companies, as well as for established companies seeking significant business growth and renewal through the development of a new innovation. The call is open until August 31, 2026.

What kind of projects are funded?

Sprint funding is granted to projects that develop new and innovative solutions and assess their technical feasibility, customer demand, and market potential. The maximum amount of funding is EUR 100,000. Applicant companies are required to secure at least EUR 50,000 in equity investment. You can find the detailed funding criteria and instructions for applying on Business Finland’s website.

The funding can be used for studies, plans, and initial applications related to industrial property rights. Purchased expert services are accepted as project costs. It is important to note that only purchases and work for which a written agreement or order has been made after submitting the funding application can be approved for the project. Feel free to get in touch—we are happy to assist with, for example, patentability assessments, freedom-to-operate analyses, drafting patent applications, and trademark prosecution.


Any questions? Please contact Viivi Ruusila at viivi.ruusila@laineip.fi or +358407217919

QATAR accedes to the International Trademark System

Qatar will bring the Nice Agreement into force on February 10, 2026


Qatar has officially brought the Nice Agreement into force on February 10, 2026, after depositing its instrument of accession with WIPO in November 2025. This means that all trademark applications, including new applications and those under examination, will be in accordance with the 11th edition of the Nice Classification. Class headings and broad patent claims covering all goods and services in a class will no longer be accepted, and lists of goods and services must be drawn up strictly in accordance with the accepted classes and acceptable terminology.

Therefore, applicants and trademark holders should ensure that all lists of goods and services are carefully drafted and consistent with the applicable classification and the requirements of the new practice, in order to avoid procedural objections or delays in processing the application.


Any questions? Do not hesitate to contact our trademark teamlead Reijo Kokko at reijo.kokko@laineip.fi / 0440704779

Laine IP receives medal for sustainability

Sustainability, for us, starts with the people. It is more than a mere principle – it consists of the actions we make every day. We want to offer a workplace where everyone feels supported, respected, and able to grow. Taking care of our team, and encouraging open, honest communication, helps us build trust and a shared sense of purpose, both inside the company and with the clients and partners we work with.

We also believe that long-term success comes from finding a healthy balance between our operations, the well-being of our employees, and the impact we have on the planet. We have always tried to make thoughtful choices that reduce our environmental footprint and improve the way we work, step by step. At the same time, we have aimed at running a stable and responsible business that can support our people and our customers over the long term.

By bringing the well-being of our employees and the environment into our everyday decisions, we hope to create value that lasts—for our team, our clients, and our community.

To help us with these targets, we began using Ecovadis a little bit more than a year ago. After learning how to use this sustainability rating system in a way that suits us, we have now obtained a Sustainability report, and an Ecovadis Bronze medal, that we feel very proud of.

More information from our Green Office team: go@laineip.fi or Kathy Wasström: kathy.wasstrom@laineip.fi

MIP Stars Research 2025 | The year has been outstanding for Laine IP

It is time to summarise the results of the 2025 Managing Intellectual Property (MIP) rankings for Laine IP Oy. The year 2025 has been the most successful in our firm’s history.

The following experienced professionals at Laine IP received individual MIP Star recognitions:

  • Kathy Wasström
  • Tatu Ahskog
  • Tom-Erik Hagelberg
  • Reijo Kokko
  • Joose Kilpimaa

In addition, MIP acknowledged the following experts with a Rising Star distinction:

  • Tiia-Riikka Kittilä
  • Joni Vehmas
  • Jemina Koskela
  • Liisa Sarnes-Salokoski (unranked)


The Rising Star recognition is awarded to emerging top professionals who have demonstrated exceptional expertise and dedication in the field of intellectual property.

We are especially proud that Kathy Wasström was named Practitioner of the Year 2025.

In addition to the individual recognitions, Laine IP Oy was awarded Trademark Firm of the Year for the second consecutive year.

Laine IP also retained its top-tier rankings in the firm-level categories for both Patent Prosecution and Trademark Prosecution.

Managing Intellectual Property’s IP Stars research is the most comprehensive and influential analysis of the global IP profession, evaluating leading IP practitioners across more than 70 countries. The research is based on extensive market analysis, client feedback, and peer reviews, assessing both the volume and the quality of work handled by each firm.

We would like to express our sincere gratitude to our clients for their trust, continued collaboration, and valuable feedback in industry surveys. Competition in our field is intense, and your feedback is essential in helping us continue to improve our services. These recognitions reflect our commitment to high-level expertise and personalised service—values that guide our work every day. These honours are a testament to our collective effort and to our mission: helping you protect and develop your innovations, enabling your business to thrive.

USPTO introduces new Streamlined Claim Set Pilot Program

On October 27, 2025, the USPTO introduced a new Streamlined Claim Set Pilot Program (“Program”). The Program offers a faster first Office action for applications that present only 1 independent claim and no more than 10 total claims.

The purpose of the Program is to help address the significant backlog of unexamined and pending US nonprovisional patent applications. Currently, the first Office action pendency (average number of months from application filing date to the date a first Office action) stands at 22.6 months.[1] By participating, US patent applicants may benefit from expedited review while contributing to the USPTO’s broader effort to reduce inventory, shorten pendency, and gather data for future reforms. Here are the main highlights of the program:

1. Timing

  • Start Date: October 27, 2025.
  • End Date: The earlier of October 27, 2026 or when each of the nine (9) USPTO Technology Centers have accepted approximately 200 applications into the Program. 
  • Petition Timing: Applicants must file a petition requesting participation in the Program before the first Office action (including any written restriction requirement).
  • Also, importantly, the USPTO will dismiss a Program petition if the subject application is already docketed to an Examiner by the time of Petition decision.
  • If accepted into the Program, the application is advanced out of turn (special docket) until the first Office action. After that, that application reverts to the regular docket.

2. Eligibility Requirements

a.       Type of Application:

  • The application must be a non-continuing (i.e., not a divisional, continuation, or continuation-in-part (CIP) application) utility application under 35 U.S.C. 111(a).
  • The application may claim priority to a prior provisional or foreign application.
  • The application must have been filed before October 27, 2025.
  • National-stage 371, continuation/divisional/CIP applications are not eligible.
  • No inventor or joint inventor may have been named on more than three (3) other nonprovisional applications for which a Petition under this Program was filed.

b.       Claim Limits:

  • No more than 1 independent claim.
  • No more than 10 total claims.
  • No multiple dependent claims.
  • All dependent claims must follow a specific dependency format (e.g., same statutory class).
  • The 1/10 limit remains throughout prosecution. Any attempt to add claims that would result in more than one independent claim and/or more than ten total claims will be treated as not fully responsive.

3. Filing Requirements

  • Specification, claims and abstract must be in DOCX format at time of filing.
  • The Petition for the Program must be submitted via Form PTO/SB/472 with the fee under 37 CFR 1.17(h) (150 USD / large entity).
  • A Preliminary Amendment reducing claims and/or bringing claims into compliance with the Program may be filed with the Petition.
  • Applicants are given a single opportunity to file the Petition. Deficiencies cannot be corrected after dismissal.
  • The is no option for withdrawal. Once accepted into the Program, Applicant cannot withdraw.
  • More information here


If you have any interest or questions about the USPTO Streamlined Claim Set Pilot Program, please do not hesitate to contact a member of our US IP Team.

[1] https://www.uspto.gov/dashboard/patents/pendency.html